Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

Biopharma Innovation in Trouble?

September 1, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

ADVERTISEMENT

Click here